Given Imaging's M2A to be Reimbursed by Horizon Blue Cross Blue Shield of New Jersey
33 Million Patients Now Have Reimbursable Access to M2A Diagnostic System

22 August 2002 - ATLANTA -- Given Imaging, Inc. (NASDAQ: GIVN) announced today that Horizon Blue Cross Blue Shield of New Jersey announced reimbursement coverage of capsule endoscopy for the small intestine. Horizon is New Jersey’s largest health insurer and provides healthcare coverage to its more than 2.5 million members. Horizon will offer capsule endoscopy reimbursement to those among its beneficiaries who may suffer from diseases of the small intestine within the noted indications.

"The capsule technology has gone well beyond the realm of an experimental device and its benefits to patients are proven. There is no question that it is a valuable and effective technology that should be universally covered by providers and utilized by physicians in diagnosing the small intestine," stated Dr. Jeffrey Hartford, a Gastroenterologist at the Hunterdon Medical Center in Flemington, New Jersey.

This press release contains forward-looking statements, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," "intends" and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03